Ticker Hub
PRTA — AI Analysis & Sentiment
4 recent AI-generated analyses for PRTA. Sentiment and confidence insights updated continuously.
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
Prothena's partner Novo Nordisk has received FDA Fast Track Designation for Coramitug, signaling accelerated development and review for a promising...
Apr 27, 2026Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
Prothena received a $50 million milestone payment for achieving an enrollment target in a Phase 3 clinical trial for its drug Coramitug. This payme...
Mar 10, 2026Prothena Announces up to $100 Million Share Repurchase Plan
Prothena's board authorizing a significant share repurchase signals strong confidence in the company's valuation, which could boost share price. Ho...
Feb 28, 2026Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena's latest financial results and 2026 guidance show a solid cash runway and significant pipeline progress. This advances the company's valua...
Feb 19, 2026